These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 4946082)
21. [On the treatment of malignant tumors with podophyllotoxin derivatives]. Goldschmidt F; Busch W Arch Ohren Nasen Kehlkopfheilkd; 1965; 185(2):815-20. PubMed ID: 5881127 [No Abstract] [Full Text] [Related]
22. Effect of podophyllum products S.P.I.&S.P.G. on malignant diseases. Datta H; Biswas S Indian J Cancer; 1968 Jun; 5(2):152-9. PubMed ID: 5688054 [No Abstract] [Full Text] [Related]
23. [Observations on the treatment of lung cancer with a podophyllum derivative (SP-1)]. Tansini G; Corti M; Gandini D; Zacco R G Ital Chemioter; 1965; 12(1):46-66. PubMed ID: 5881986 [No Abstract] [Full Text] [Related]
25. Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer. Slack NM; Jones R Cancer Chemother Rep; 1970 Feb; 54(1):53-63. PubMed ID: 4945998 [No Abstract] [Full Text] [Related]
26. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. European Organization for Research on the Treatment of Cancer, Clinical Screening Group Br Med J; 1973 Jul; 3(5873):199-202. PubMed ID: 4578134 [TBL] [Abstract][Full Text] [Related]
29. Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma. Gottlieb JA; Frei E; Luce JK Cancer Chemother Rep; 1971 Jun; 55(3):277-80. PubMed ID: 5115848 [No Abstract] [Full Text] [Related]
30. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung. Weiss AJ; Wilson WL Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850 [No Abstract] [Full Text] [Related]
31. [Clinical studies of the method of application of antineoplastic agents]. Furue H; Nakao I; Hattori T; Yamana T; Kubo A Gan No Rinsho; 1970 Sep; 16(9):896-909. PubMed ID: 5528959 [No Abstract] [Full Text] [Related]
32. Further clinical studies of trimethylpurin-6-ylammonium chloride (NSC-51095) in malignant disease with special emphasis on cancer of urinary bladder. Phillips RW Cancer Chemother Rep; 1970 Jun; 54(3):181-5. PubMed ID: 4947750 [No Abstract] [Full Text] [Related]
33. Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle. Misra NC; Roberts DW Cancer Res; 1975 Jan; 35(1):99-105. PubMed ID: 1053697 [TBL] [Abstract][Full Text] [Related]
34. [Observations on the therapy of primary cancer of the lung (sample research on 100 subjects treated)]. Massei V Rass Int Clin Ter; 1967 Jun; 47(12):642-50. PubMed ID: 5607587 [No Abstract] [Full Text] [Related]
36. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). Creaven PJ; Newman SJ; Selawry OS; Cohen MH; Primack A Cancer Chemother Rep; 1974; 58(6):901-7. PubMed ID: 4615787 [No Abstract] [Full Text] [Related]
37. [Concerning a new glycoside preparation method. Synthesis of epidopodophyllotoxin-beta-D-glucopyranoside]. Kuhn M; von Wartburg A Helv Chim Acta; 1968 Oct; 51(7):1631-41. PubMed ID: 5688036 [No Abstract] [Full Text] [Related]
38. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma. Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016 [No Abstract] [Full Text] [Related]
39. Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065). Creasey WA; Capizzi RL; DeConti RC Cancer Chemother Rep; 1970 Jun; 54(3):191-4. PubMed ID: 4946005 [No Abstract] [Full Text] [Related]
40. [Experimental bases and clinical aspects of the use of 2 antimitotic derivatives of podophyllum]. Fanchamps A J Med (Oporto); 1965 Nov; 58(191):673-92. PubMed ID: 5215285 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]